NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel
    COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel
    India

    COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel

    Written by Ramya Patelkhana
    May 12, 2021 | 11:03 am 2 min read
    COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel
    Credits
    COVAXIN gets nod for phase 2/3 trials on 2-18 year-olds

    In a bid to extend the country's vaccination drive to include people below 18 years, an expert panel on Tuesday recommended Hyderabad-based Bharat Biotech's COVID-19 vaccine COVAXIN for phase 2/3 clinical trials on children and adolescents aged two to 18 years. The trials would be conducted on 525 subjects across numerous sites, including AIIMS-Delhi, AIIMS-Patna, and Meditrina Institute of Medical Sciences, Nagpur, among others.

    Children likely at higher risk in possible third wave: Experts

    Notably, this development comes amid reports that the possible third COVID-19 wave in India is likely to be dangerous for children. Experts say that the first wave affected older people, and in the ongoing second wave, youngsters are getting more infected, while the third wave could see more infections in children. Hence, ensuring vaccination of children is crucial to prepare for the third wave.

    Expert panel's nod for COVAXIN trials on those below 18

    The approval by the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) came after the expert panel deliberated in detail on Bharat Biotech's application that sought permission to initiate phase 2/3 trials. The COVAXIN maker sought to conduct the trials to assess the safety, reactogenicity, and immunogenicity of its vaccine in those aged between two to 18 years.

    Should submit phase-2 safety data before proceeding to phase-3

    "The committee recommended for conduct of proposed phase 2/3 clinical trial of whole virion inactivated coronavirus vaccine in the 2 to 18 years age group," PTI quoted a source as saying. Bharat Biotech should "submit the interim safety data of phase 2 clinical trial along with DSMB (data and safety monitoring board) recommendations to the CDSCO before proceeding to phase 3," added the source.

    Centre dismissed false claims regarding COVAXIN for those above 12

    Earlier on February 24, the SEC deliberated on the proposal by Bharat Biotech following which the vaccine maker was directed to submit a revised protocol for the clinical trials. Recently, false claims have been doing the rounds on social media that the Centre has approved COVAXIN for those aged above 12 years. However, the government dismissed these claims, clarifying that the news is fake.

    COVAXIN is currently being administered only to adults

    To note, COVAXIN is one of the vaccines that are being administered as part of India's vaccination drive. It is currently being used only in adults. The vaccine has been developed indigenously by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR).

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Vaccine
    Central Drugs Standard Control Organization (CDSCO)
    COVID-19
    Bharat Biotech
    COVAXIN

    Vaccine

    States to receive seven lakh additional COVID-19 vaccine doses: Centre Union Health Ministry
    AstraZeneca vaccine's single dose reduces death risk by 80%: Data Pfizer
    Going for vaccination? What to do before and after jab India
    COVID-19 vaccine offers minimal protection to organ transplant recipients: Study Research

    Central Drugs Standard Control Organization (CDSCO)

    Foreign COVID-19 vaccines: Decision on EUA applications within three days Coronavirus
    Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial Drugs Controller General of India
    Coronavirus vaccine: Bharat Biotech's COVAXIN gets expert panel nod Union Health Ministry
    India set to start COVID-19 vaccination; panel approves Oxford vaccine Oxford

    COVID-19

    Assam Masjid Committees: No Eid mass prayers due to COVID-19 Assam
    Twenty-nine new COVID-19 cases reported at IIT Jodhpur Jodhpur
    Disinfection drives, 'kadha': Here's how farmers are fighting the virus Farmers Protest
    Nadda writes to Sonia Gandhi, slams the Congress over COVID-19 Sonia Gandhi

    Bharat Biotech

    Truck laden with COVAXIN abandoned for 12 hours, driver missing Madhya Pradesh
    Bharat Biotech reduces COVAXIN price to Rs. 400 for states Vaccine
    Bharat Biotech to produce 700 million COVAXIN doses per year COVID-19
    COVAXIN manufacturing facility fails to meet CGMP standards: Brazilian regulator Brazil

    COVAXIN

    COVAXIN doses unavailable for second consecutive day in Mumbai Mumbai
    Indian vaccine found effective against new COVID-19 variant: Dr. Fauci India
    Coronavirus: 0.04% people infected after COVAXIN shot; 0.03% after Covishield Vaccine
    COVAXIN neutralizes double mutant strain: ICMR Indian Council of Medical Research (ICMR)
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023